- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03360669
Comparison of Blood Pressure Measurement With an Omron HEM-907 Device in a Clinical Setting and a Research Setting (OMRONHEM-907)
10. april 2018 opdateret af: Maxime Lamarre-Cliche, Institut de Recherches Cliniques de Montreal
Automated office blood pressure (AOBP) devices are recommended for high blood pressure diagnosis.
One of those devices is the Omron HEM-907 (Omron Healthcare).
It is currently not known if blood pressure measurements performed with this device in a clinical setting are equivalent to those made in a research setting.
Therefore, this randomized-controlled trial was designed.
It aims to compare the blood pressure measurements performed in a clinical and a research setting.
Seventy patients will be included and randomized to a clinical/research or research/clinical sequence.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Hypertension is a common condition, with an estimated prevalence around 20 percent in Canada.
It is a major risk factor for cardiovascular disease.
Recently, Hypertension Canada has updated its guidelines and recommend we should consider a 120 mm Hg systolic blood pressure target in high-risk patients aged 50 years or older.
This recommendation derives mainly from the SPRINT trial.
In this trial, blood pressure was measured with an automated oscillometric blood pressure (AOBP) device, the Omron HEM-907 (Omron Healthcare).
However, it is not known if measurements performed with this device in a clinical setting are equivalent to those made in a research setting.
Therefore, this randomized-controlled trial was designed.
It aims to compare the blood pressure measurements of 70 patients in a clinical and a research setting.
Patients will be randomized to a clinical/research or a research/clinical sequence.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
70
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Quebec
-
Montreal, Quebec, Canada, H2W1R7
- Institut de recherches cliniques de Montreal
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- At least 18 years old
- Hypertensive or presumed hypertensive
- Patients with a scheduled visit at the IRCM hypertension clinic.
Exclusion Criteria:
- Limitation preventing the measurement of blood pressure
- Introduction or withdrawal of any blood pressure-modifying medication starting 4 weeks before the first and until the last study visit.
- Recreative drug use (except cannabis)
- Alcohol use of more than 4 drinks during the day
- New symptoms during the research visit, that warrants a medical evaluation
- Mean systolic blood pressure >180 mm Hg or mean diastolic blood pressure >110 mm Hg (using AOBP)
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Diagnostisk
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Sequence: Clinical/Research
Participants assigned to this arm will have their blood pressure measured in a clinical setting first, and in a research setting second.
The sequence randomization corresponds to the intervention.
Visits will be at least a day apart but within a two-week period.
During the clinical visit, they will have their blood pressure measured with the Omron HEM-907, an automated office blood pressure (AOBP) device.
During the research setting, participants will be guided through a series of research-driven steps such as study questionnaires and completion of consent forms.
They will have their blood pressure measured in both arms with a mercury sphygmomanometer, and then 3 measurements with a mercury sphygmomanometer.
AOBP measurements (Omron HEM-907) will be performed at the end of the visit.
|
Participants will be assigned to a sequence of: research visit first/clinical visit second.
|
|
Aktiv komparator: Sequence: Research/Clinical
Participants assigned to this arm will go through the same measurements and procedures exception made of the research-first and clinical-second sequence.
The intervention to which they are randomized corresponds to the sequence of the visits.
|
Participants will be assigned to a sequence of: clinical visit first/research visit second.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Mean automated office blood pressure systolic blood pressure estimates
Tidsramme: Up to 2 weeks
|
Up to 2 weeks
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Mean automated office blood pressure diastolic blood pressure estimates.
Tidsramme: Up to 2 weeks
|
Up to 2 weeks
|
|
Individual unaveraged automated office systolic and diastolic blood pressure measurements (1, 2 and 3)
Tidsramme: Up to 2 weeks
|
Up to 2 weeks
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016 Mar 5;387(10022):957-967. doi: 10.1016/S0140-6736(15)01225-8. Epub 2015 Dec 24.
- Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? JAMA. 1988 Jan 8;259(2):225-8.
- Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, Nerenberg K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tran KC, Tobe SW, Ruzicka M, Burns KD, Vallee M, Prasad GVR, Gryn SE, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Sivapalan P, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NRC, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Kline G, Leiter LA, Jones C, Cote AM, Woo V, Kaczorowski J, Trudeau L, Tsuyuki RT, Hiremath S, Drouin D, Lavoie KL, Hamet P, Gregoire JC, Lewanczuk R, Dresser GK, Sharma M, Reid D, Lear SA, Moullec G, Gupta M, Magee LA, Logan AG, Dionne J, Fournier A, Benoit G, Feber J, Poirier L, Padwal RS, Rabi DM; Hypertension Canada. Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Can J Cardiol. 2017 May;33(5):557-576. doi: 10.1016/j.cjca.2017.03.005. Epub 2017 Mar 10. Erratum In: Can J Cardiol. 2017 Dec;33(12 ):1733-1734.
- SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9. Erratum In: N Engl J Med. 2017 Dec 21;377(25):2506.
- Padwal RS, Bienek A, McAlister FA, Campbell NR; Outcomes Research Task Force of the Canadian Hypertension Education Program. Epidemiology of Hypertension in Canada: An Update. Can J Cardiol. 2016 May;32(5):687-94. doi: 10.1016/j.cjca.2015.07.734. Epub 2015 Aug 15.
- Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996 May 22-29;275(20):1571-6.
- Myers MG, Valdivieso MA. Use of an automated blood pressure recording device, the BpTRU, to reduce the "white coat effect" in routine practice. Am J Hypertens. 2003 Jun;16(6):494-7. doi: 10.1016/s0895-7061(03)00058-x.
- Edwards C, Hiremath S, Gupta A, McCormick BB, Ruzicka M. BpTRUth: do automated blood pressure monitors outperform mercury? J Am Soc Hypertens. 2013 Nov-Dec;7(6):448-53. doi: 10.1016/j.jash.2013.07.002. Epub 2013 Aug 19.
- Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Grant FC, Kaczorowski J. Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. BMJ. 2011 Feb 7;342:d286. doi: 10.1136/bmj.d286.
- Myers MG, Oh PI, Reeves RA, Joyner CD. Prevalence of white coat effect in treated hypertensive patients in the community. Am J Hypertens. 1995 Jun;8(6):591-7. doi: 10.1016/0895-7061(95)00049-U.
- Myers MG, Valdivieso M, Kiss A. Consistent relationship between automated office blood pressure recorded in different settings. Blood Press Monit. 2009 Jun;14(3):108-11. doi: 10.1097/MBP.0b013e32832c5167.
- Agarwal R. Implications of Blood Pressure Measurement Technique for Implementation of Systolic Blood Pressure Intervention Trial (SPRINT). J Am Heart Assoc. 2017 Feb 3;6(2):e004536. doi: 10.1161/JAHA.116.004536.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
27. november 2017
Primær færdiggørelse (Faktiske)
29. marts 2018
Studieafslutning (Faktiske)
29. marts 2018
Datoer for studieregistrering
Først indsendt
17. november 2017
Først indsendt, der opfyldte QC-kriterier
1. december 2017
Først opslået (Faktiske)
4. december 2017
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
11. april 2018
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
10. april 2018
Sidst verificeret
1. april 2018
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- OMRON HEM-907
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
JA
IPD-planbeskrivelse
according to specific scientifically pertinent demands
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Forhøjet blodtryk
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyIkke rekrutterer endnu
-
VIVUS LLCIkke rekrutterer endnuPulmonal arteriel hypertension | Pulmonal arteriel hypertension (PAH) (WHO Group 1 PH) | Pulmonal arteriel hypertension (PAH) | Pulmonal arteriel hypertension WHO gruppe I | Pulmonal arteriel hypertension PAH
-
BayerAfsluttet
-
National Taiwan University Hospital Hsin-Chu BranchRekrutteringHypertension, essentiel | Hypertension, maskeretTaiwan
-
BackBeat Medical IncIkke rekrutterer endnuHypertension, systolisk | Hypertension (HTN) | Hjertesvigt med bevaret ejektionsfraktion (HFpEF)Georgien
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc...Ikke rekrutterer endnuPulmonal hypertension | Pulmonal arteriel hypertension (PAH)Forenede Stater
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)Forenede Stater
-
University of Sao Paulo General HospitalRekrutteringPulmonal arteriel hypertension (PAH)Brasilien
-
University Hospital, BrestIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)Frankrig
-
Shanghai Zhongshan HospitalIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)
Kliniske forsøg med Sequence: Clinical/Research
-
Thomas Jefferson UniversityAfsluttetHæmatopoietisk og lymfoid celle-neoplasma | Ondartet fast neoplasmaForenede Stater
-
Wake Forest University Health SciencesThe Susanne Marcus Collins Foundation, Inc.AfsluttetStress | Angst | Sundhedspersonale | Akustisk stimulering | Hyperarousal | Autonom dysreguleringForenede Stater
-
Wake Forest University Health SciencesThe Susanne Marcus Collins Foundation, IncAfsluttetCovid19 | Stress | Søvnløshed | Angst | Coronavirusinfektion | Sundhedspersonale | HyperarousalForenede Stater
-
Wake Forest University Health SciencesSusanne Marcus Collins Foundation; Gastroenterology ProjectTrukket tilbageLivskvalitet | Kvalme | Opkastning | Stress | Angst | Gastroparese | Hjertefrekvensvariation | HyperarousalForenede Stater
-
Madigan Army Medical CenterTelemedicine & Advanced Technology Research Center; Analytics4Medicine,...AfsluttetUkontrolleret hypertensionForenede Stater
-
PoppinsLindus HealthRekrutteringOrdblindhed | Indlæringsvanskeligheder | Indlæringsforstyrrelse, specifik | Specifik indlæringsforstyrrelse, med nedsat læseevneFrankrig
-
University of ConnecticutNational Institutes of Health (NIH); National Center for Complementary...Afsluttet
-
Wake Forest University Health SciencesMemory Counseling Program general fund; Heidi Munger-Clary, MD; Hossam Shaltout... og andre samarbejdspartnereRekruttering
-
Wake Forest University Health SciencesThe Susanne Marcus Collins Foundation, Inc.Tilmelding efter invitationDepression | Stress | Søvnløshed | Angst | SundhedspersonaleForenede Stater
-
Mayo ClinicAfsluttetBryst Neoplasma Kvinde | Ultralydsterapi; KomplikationerForenede Stater